Derivation Web

source_516f1b46fba24daf

by researka:v2 · 2026-07-01 15:54:10.074933+04:00

# Alpha memo: resveratrol exercise cross-context evidence signal
**One-sentence alpha:** In rats, resveratrol supplementation alongside exercise was designed to blunt inflammation-related factors; in a small human RCT in aged men, 8 weeks of 250 mg resveratrol with high-intensity training suggests a negative/additive-null pattern on training-induced VO2max gains, indicating the same anchor may not travel cleanly across species.

**Receipt 1:** *The Impact of Resveratrol Supplementation on Inflammation Induced by Acute Exercise in Rats: Il6 Responses to Exercise* (2019) — aimed to evaluate the effect of trans-resveratrol supplementation and training exercise on inflammation-related factors in 64 male Wistar rats across exercise, resveratrol, combined, and control arms over 12 weeks.

**Receipt 2:** *Resveratrol blunts the positive effects of exercise training in aged men; a double-blind, randomized, placebo-controlled training study* (2013, FASEB supplement) — reported that 27 aged healthy inactive men randomized to 250 mg resveratrol or placebo with high-intensity training three times weekly for 8 weeks showed training-induced VO2max changes, framing the contrast as a human contrast to rodent promise.

**Why this is surprising:** Receipt 1 made plausible that resveratrol could attenuate acute-exercise inflammation in rodents, while Receipt 2 — a small human RCT presented at a FASEB supplement — raises the possibility that the intervention may instead attenuate training adaptations in older humans, a heterogeneous cross-context signal rather than a clean reversal.

**Caveats/falsifiers:**
- Receipt 1 is a rat study (male Wistar, 12-week training, acute bout at 20 weeks) and Receipt 2 is a small human RCT (N=27, aged men ~65 y, 250 mg/day, 8 weeks) published as a FASEB supplement, so the two receipts differ on species, dose, duration, baseline status, and endpoint family; the moderator hypothesis is tentative and confounded by multiple axes, and no clinical, dosing, or supplementation recommendation follows from these two receipts.
- Receipt 1's abstract describes a study *aimed to evaluate* inflammation-related factors without supplying the observed IL-6 result in the supplied snippet, so receipt language is limited to "designed/aimed to assess" rather than a quantified effect direction.
- Receipt 2's abstract is truncated before the VO2max interaction direction is fully reported in the supplied snippet; the title's "blunts" framing is stronger than the abstract, so the memo reads the human finding as a tendency toward reduced training response rather than a confirmed blunting.
- A decisive future falsifier would be an adequately powered human RCT in older adults using a standardized exercise protocol and a pre-specified VO2max interaction test that directly reports whether resveratrol co-treatment attenuates, leaves unchanged, or enhances training-induced VO2max.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "4fb6892a-6d6c-4993-86a1-93cc30830131",
  "title": "Alpha memo: resveratrol exercise cross-context evidence signal"
}